

WHAT IS CLAIMED IS:

1. A medical device comprising:
an implantable structure; and
5 a histone deacetylase inhibitor, in therapeutic dosages,
releasably affixed to the implantable structure for the treatment of restenosis
following vascular injury.
2. The medical device according to Claim 1, wherein the
10 implantable structure comprises a stent.
3. The medical device according to Claim 1, wherein the
implantable structure comprises a stent-graft.
- 15 4. The medical device according to Claim 1, wherein the histone
deacetylase inhibitor comprises trichostatin A.
5. The medical device according to Claim 1, further comprising a
polymeric coating, the histone deacetylase inhibitor being incorporated into
20 the polymeric coating.
6. A medical device comprising:
an implantable structure;
a histone deacetylase inhibitor, in thereapeutic dosages,
25 releasably affixed to the implantable structure for the treatment of restenosis
following vascular injury; and
an anti-proliferative, in therapeutic dosages, releasably affixed to
the implantable structure for the treatment of restenosis following vascular
injury.
30
7. The medical device according to Claim 6, wherein the
implantable structure comprises a stent.

8. The medical device according to Claim 6, wherein the implantable structure comprises a stent-graft.

5 9. The medical device according to Claim 6, wherein the histone deacetylase inhibitor comprises trichostatin A.

10. The medical device according to Claim 9, wherein the anti-proliferative comprises rapamycin.

10 11. The medical device according to Claim 10, further comprising a polymeric coating, the histone deacetylase inhibitor and the anti-proliferative being incorporated into the polymeric coating.

15 12. A medical device comprising:
a delivery structure; and
a histone deacetylase inhibitor, in therapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury.

20 13. A medical device comprising:
a delivery structure;
a histone deacetylase inhibitor, in thereapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury; and
25 an anti-proliferative, in therapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury.

14. A method for treating restenosis comprising the local administration of a therapeutic dose of a histone deacetylase inhibitor.